In our final installation of The Long-Covid of Pharma Marketing series, we deep dive into the shifting attitudes towards vaccines across the board. The pandemic may have faded from headlines, but its aftershocks continue to ripple through one of healthcare’s most crucial pillars: vaccination.

The fourth blog in this series looks at the effect of the pandemic on healthcare professionals (HCPs). As we put more and more distance between ourselves and COVID-19, the spotlight on HCPs continues to dim; nevertheless, the emotional and psychological toll of the pandemic still lingers in the minds of these brave frontline workers and their families.

In the evolving landscape of healthcare, artificial intelligence (AI) is making significant strides – not just in diagnostics and treatment but also in understanding patient experiences. Together with voice and emotion analysis AI company, Phebi, we have pioneered a new approach that combines AI with primary research to uncover deeper insights into patient experiences of rare diseases.

While the growth and advancement of AI has yielded greater automation and efficiencies, it has completely reshaped patient engagement – and as a result, we risk losing something invaluable – the human connection that enables real understanding, trust, and advocacy.

In this third blog of The Long-Covid of Pharma Marketing series, we explore the transformed healthcare landscape, where telehealth has emerged as a cornerstone of care delivery.

In this second blog of The Long-Covid of Pharma Marketing series, we investigate one of the most enduring tensions to have grown from the pandemic: misinformation.

This is the first blog of our series on The Long-Covid of Pharma Marketing. Here we’ll revisit the five key tensions that have emerged from and endured beyond the pandemic into pharma marketing’s own long-covid. Today, we explore the growing crisis of vaccine hesitancy and distrust in healthcare.